Skip to main content
. Author manuscript; available in PMC: 2013 Nov 15.
Published in final edited form as: Clin Cancer Res. 2012 Sep 26;18(22):6296–6305. doi: 10.1158/1078-0432.CCR-12-0668

Figure 3.

Figure 3

Dose-dependent increase in ADCC induced by anti-CD19 XmAb5574 or anti-CD33 lintuzumab. (A) MLL-rearranged leukemia cells were treated with XmAb5574 antibody at doses ranging from 10−3 to 103 ng/mL in the presence of NK cells (1:20 targets to effectors). (B) MLL-rearranged leukemia cells were treated with lintuzumab antibody at doses from 10−1 to 104 ng/mL. Isotype IgG antibody was used as a negative control. Data are mean ± S.E.M. from five independent experiments.